Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disorder marked by alternating periods of relapse and remission. This multicenter, randomized, active- and vehicle-controlled, investigator-blinded study compared the efficacy and safety of clobetasol propionate lotion to clobetasol propionate cream formulation and lotion vehicle in the treatment of moderate to severe AD. A total of 229 subjects applied treatment twice-daily for 2 weeks. Clobetasol propionate lotion was significantly more effective than its lotion vehicle at 2 weeks and comparable to the cream formulation. Clinical success after a 2-week, treatment-free follow-up period was greater in the clobetasol propionate lotion group than in the cream group. Clobetasol propionate lotion is effective, safe, well tolerated and offers a better remission profile in the treatment of moderate to severe AD as compared to clobetasol propionate emollient cream.
Breneman
Debra
D
Dermatology Clinical Research Institute, Cincinnati, OH, USA.
Fleischer
Alan B
AB
Kaplan
David
D
Lebwohl
Mark
M
Miller
Bruce
B
Pariser
David
D
Rist
Toivo
T
Swinyer
L
L
Liu
Yin
Y
Foley
Valerie
V
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002626:Chemistry, Pharmaceutical; D002648:Child; D002990:Clobetasol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004643:Emollients / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method
D004643:Emollients; D002990:Clobetasol